# ABBVIE INC. (ABBV) — Stock CV

Abbvie Inc. is a $488B healthcare company. Revenue grew 10.4% over the last year, it keeps 10¢ of every dollar of sales as profit, and its net debt equals ~3.1 years of free cash flow. It trades at 77.4× earnings — in the most expensive third of its own history.

> AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

## Identity

- **Ticker**: ABBV
- **Sector**: Healthcare
- **Industry**: Drug Manufacturers - General
- **Headquarters**: NORTH CHICAGO, IL
- **Employees**: 57 000
- **Website**: https://www.abbvie.com
- **Market cap**: $488B
- **Last price**: $276.43
- **Financial profile**: Mixed

## Vitals (TTM)

- **Revenue**: $64.4B
- **Net income**: $6.31B
- **Free cash flow**: $18.2B
- **Net debt**: $56.2B
- **P/E**: 77.4
- **Revenue growth (YoY)**: 10.4%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 34 |
| Growth | 31 |
| Profitability | 68 |
| Health | 39 |
| Quality | 95 |
| Moat | 88 |

## Qualifications (beginner checklist) — 9 of 11 passed

- [x] Revenue growing — +10.4% YoY
- [x] Profitable — $6.31B TTM
- [ ] Profit growing — -29.0% YoY
- [x] Generates cash — $18.2B TTM
- [x] Debt under control — ~3.1y of cash flow to repay
- [x] Established company — $488B market cap
- [x] Not printing shares — +6.0% shares over ~5y
- [x] Proven track record — 10/10 profitable years
- [x] Financially stable — Altman Z 2.3 — grey
- [x] Pays a dividend — yield 2.45%
- [ ] Valuation not extreme — P/E 77.4

## Experience (career milestones)

- **2026** — AbbVie struck a deal with the Trump administration to invest $100 billion in its US operations over…
- **2025** — AbbVie acquired Bretisilocin, which is under development for the treatment of major depressive…
- **2024** — AbbVie acquired ImmunoGen for $10.1 billion, aiming to expedite its entry into the ovarian cancer…
- **FY2022** — Best year on record: $11.8B net income
- **2022** — AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of…
- **FY2021** — Revenue crossed $50B: $56.2B for the year
- **2021** — Allergan Aesthetics announced the acquisition of Soliton
- **2019** — AbbVie announced it would acquire Irish-based Allergan plc for about $63 billion
- **FY2016** — Profitable every year on record: 10 consecutive profitable years in our data
- **FY2016** — Revenue already above $10B: $25.6B in first reported year
- **FY2016** — Positive free cash flow every year since: 10-year streak
- **2015** — AbbVie acquired oncology firm Pharmacyclics and its treatment for blood cancers, ibrutinib
- **2014** — AbbVie ended its efforts to acquire Shire, which would have been one of the largest mergers and…
- **2013** — It became a public company in January 2013
- **2012** — AbbVie was formed in 2012 as a corporate spin-off from Abbott Laboratories

## Strengths

- High gross margin (72.8%)
- Revenue growing 10.4% year over year
- Strong cash conversion — FCF is 28.3% of revenue
- Piotroski F-Score 8/9 — fundamentally strong checklist

## Watch-outs

- None stand out in the data.

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $56.2B | $11.5B | $22.0B |
| FY2022 | $58.1B | $11.8B | $24.2B |
| FY2023 | $54.3B | $4.86B | $22.1B |
| FY2024 | $56.3B | $4.28B | $17.8B |
| FY2025 | $61.2B | $4.23B | $17.8B |

---

Source: https://stockcv.com/ABBV — derived from company filings; may be delayed or incomplete. Information, not investment advice.